Diurnal Group plc – LSE:DNL.L

Diurnal Group stock price today

GBP 57
+29.7
+108.79%

Diurnal Group stock price monthly change

+0.55%
month

Diurnal Group stock price quarterly change

+176.46%
quarter

Diurnal Group stock price yearly change

-54.65%
year

Diurnal Group key metrics

Market Cap
 N/A
Enterprise value
 N/A
P/E
 -0.03
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 4.11
Price/Book
 1.20
PEG ratio
 N/A
EPS
 1.75
Revenue
 1.69B
EBITDA
 390.23M
Income
 282.57M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 -64.5%
Oper. margin
 -85.41%
Gross margin
 89.42%
EBIT margin
 -85.41%
EBITDA margin
 23.04%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Diurnal Group stock price history

Diurnal Group stock forecast

Diurnal Group financial statements

Profit Margin

Diurnal Group plc (LSE:DNL.L): Profit margin
Sep 2022 459.29M 93.22M 20.3%
Dec 2022 426.18M 51.86M 12.17%
Mar 2023 401.89M 68.90M 17.14%
Jun 2023 406.70M 68.58M 16.86%
DNL.L income statement history

Debt to Assets

Diurnal Group plc (LSE:DNL.L): Debt to assets
Jun 2020 20976000 2.59M 12.35%
Dec 2020 26364000 3.22M 12.23%
Jun 2021 41790000 4.22M 10.11%
Dec 2021 34565000 4.64M 13.45%
DNL.L balance sheet history

Cash Flow

Diurnal Group plc (LSE:DNL.L): Cash Flow
Sep 2022 198.70M 46.38M -57.75M
Dec 2022 120.77M -43.42M -3.22M
Mar 2023 -87.70M -190.56M 11.18M
Jun 2023 134.96M -18.11M 1.49M
DNL.L cash flow history

Diurnal Group alternative data

Diurnal Group
Employees

Diurnal Group plc (LSE:DNL.L): Employee count
Aug 2023 33
Sep 2023 33
Oct 2023 33
Nov 2023 33
Dec 2023 33
Jan 2024 33
Feb 2024 33
Mar 2024 33
Apr 2024 33
May 2024 33
Jun 2024 33
Jul 2024 33

Diurnal Group other data

Diurnal Group
Executives

Insider Compensation
Mr. Richard Edward Bungay A.C.A., B.Sc., BSc, ACA (1969) Chief Financial Officer, Company Sec. & Director
 $338,000

Frequently Asked Questions (FAQ)

  • What's the price of Diurnal Group stock today?

    One share of Diurnal Group stock can currently be purchased for approximately $57.

  • When is Diurnal Group's next earnings date?

    Unfortunately, Diurnal Group's (DNL.L) next earnings date is currently unknown.

  • Does Diurnal Group pay dividends?

    No, Diurnal Group does not pay dividends.

  • What is Diurnal Group's stock symbol?

    Diurnal Group plc is traded on the LSE under the ticker symbol "DNL.L".

  • What is Diurnal Group's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Diurnal Group?

    Shares of Diurnal Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Diurnal Group's key executives?

    Diurnal Group's management team includes the following people:

    • Mr. Richard Edward Bungay A.C.A., B.Sc., BSc, ACA Chief Financial Officer, Company Sec. & Director(age: 56, pay: $338,000)

  • How many employees does Diurnal Group have?

    As Jul 2024, Diurnal Group employs 33 workers.

  • When Diurnal Group went public?

    Diurnal Group plc is publicly traded company for more then 9 years since IPO on 24 Dec 2015.

  • What is Diurnal Group's official website?

    The official website for Diurnal Group is diurnal.co.uk.

  • How can i contact Diurnal Group?

    Diurnal Group can be reached via phone at +44 29 2068 2069.

Diurnal Group company profile:

Diurnal Group plc

diurnal.co.uk
Exchange:

LSE

Full time employees:

33

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers an oral formulation of hydrocortisone granules in capsules for the treatment of pediatric adrenal insufficiency. It also develops Chronocort, which completed Phase II clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early-stage pipeline products comprise Ditest, a native oral testosterone product, which has completed phase I clinical trial for the treatment of classical hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (triiodothyronine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.

+44 29 2068 2069
Cardiff MediCentre
Cardiff, CF14 4UJ

:
ISIN: GB00BDB6Q760
CUSIP: G2772R105